Skip to content
Erudio Health
menu
Clinical trial · no report yet · Phase 3

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

  • NCT05257083 ↗
  • Active not recruiting
  • Stichting European Myeloma Network
  • 110 commentary sources found
  • Deep

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Commentary we found

Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.

ChannelFound
YouTube62
Podcasts27
X threads20
X videos1

The trial

ClinicalTrials.gov
Official title
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Phase
Phase 3
Status
Active not recruiting
Conditions
Multiple Myeloma
Interventions
Daratumumab; Bortezomib; Lenalidomide; Dexamethasone; Cilta-cel; Cyclophosphamide; Fludarabine
Arms
  • Arm A: DVRd + ASCT+DVRd (Standard Therapy) · Active comparator
  • Arm B: DVRd followed by Ciltacabtagene Autoleucel · Experimental
Enrollment
759
Primary outcomes
  • Progression free survival (PFS)
  • Sustained MRD-negative CR
Sponsor
Stichting European Myeloma Network with Janssen Research & Development, LLC
Start
Oct 10, 2023
Primary completion
Jun 2033 (estimated)
Results posted
No
Registry record
NCT05257083 · updated Mar 17, 2026